A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer
Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of...
Saved in:
| Published in | Biomolecules (Basel, Switzerland) Vol. 11; no. 12; p. 1749 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
23.11.2021
MDPI |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2218-273X 2218-273X |
| DOI | 10.3390/biom11121749 |
Cover
Loading…
| Abstract | Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of tumors, including ovarian cancer. Kidney-type glutaminase (GLS), as one of the isotypes of glutaminase, is found to promote tumorigenesis. Here, we have demonstrated that the combined treatment with GLS inhibitor 968 and PD-L1 blockade enhances the immune response against ovarian cancer. Survival analysis using the Kaplan–Meier plotter dataset from ovarian cancer patients revealed that the expression level of GLS predicts poor survival and correlates with the immunosuppressive microenvironment of ovarian cancer. 968 inhibits the proliferation of ovarian cancer cells and enhances granzyme B secretion by CD8+ T cells as detected by XTT assay and flow cytometry, respectively. Furthermore, 968 enhances the apoptosis-inducing ability of CD8+ T cells toward cancer cells and improves the treatment effect of anti-PD-L1 in treating ovarian cancer as assessed by Annexin V apoptosis assay. In vivo studies demonstrated the prolonged overall survival upon combined treatment of 968 with anti-PD-L1 accompanied by increased granzyme B secretion by CD4+ and CD8+ T cells isolated from ovarian tumor xenografts. Additionally, 968 increases the infiltration of CD3+ T cells into tumors, possibly through enhancing the secretion of CXCL10 and CXCL11 by tumor cells. In conclusion, our findings provide a novel insight into ovarian cancer cells influence the immune system in the tumor microenvironment and highlight the potential clinical implication of combination of immune checkpoints with GLS inhibitor 968 in treating ovarian cancer. |
|---|---|
| AbstractList | Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of tumors, including ovarian cancer. Kidney-type glutaminase (GLS), as one of the isotypes of glutaminase, is found to promote tumorigenesis. Here, we have demonstrated that the combined treatment with GLS inhibitor 968 and PD-L1 blockade enhances the immune response against ovarian cancer. Survival analysis using the Kaplan-Meier plotter dataset from ovarian cancer patients revealed that the expression level of GLS predicts poor survival and correlates with the immunosuppressive microenvironment of ovarian cancer. 968 inhibits the proliferation of ovarian cancer cells and enhances granzyme B secretion by CD8+ T cells as detected by XTT assay and flow cytometry, respectively. Furthermore, 968 enhances the apoptosis-inducing ability of CD8+ T cells toward cancer cells and improves the treatment effect of anti-PD-L1 in treating ovarian cancer as assessed by Annexin V apoptosis assay. In vivo studies demonstrated the prolonged overall survival upon combined treatment of 968 with anti-PD-L1 accompanied by increased granzyme B secretion by CD4+ and CD8+ T cells isolated from ovarian tumor xenografts. Additionally, 968 increases the infiltration of CD3+ T cells into tumors, possibly through enhancing the secretion of CXCL10 and CXCL11 by tumor cells. In conclusion, our findings provide a novel insight into ovarian cancer cells influence the immune system in the tumor microenvironment and highlight the potential clinical implication of combination of immune checkpoints with GLS inhibitor 968 in treating ovarian cancer.Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of tumors, including ovarian cancer. Kidney-type glutaminase (GLS), as one of the isotypes of glutaminase, is found to promote tumorigenesis. Here, we have demonstrated that the combined treatment with GLS inhibitor 968 and PD-L1 blockade enhances the immune response against ovarian cancer. Survival analysis using the Kaplan-Meier plotter dataset from ovarian cancer patients revealed that the expression level of GLS predicts poor survival and correlates with the immunosuppressive microenvironment of ovarian cancer. 968 inhibits the proliferation of ovarian cancer cells and enhances granzyme B secretion by CD8+ T cells as detected by XTT assay and flow cytometry, respectively. Furthermore, 968 enhances the apoptosis-inducing ability of CD8+ T cells toward cancer cells and improves the treatment effect of anti-PD-L1 in treating ovarian cancer as assessed by Annexin V apoptosis assay. In vivo studies demonstrated the prolonged overall survival upon combined treatment of 968 with anti-PD-L1 accompanied by increased granzyme B secretion by CD4+ and CD8+ T cells isolated from ovarian tumor xenografts. Additionally, 968 increases the infiltration of CD3+ T cells into tumors, possibly through enhancing the secretion of CXCL10 and CXCL11 by tumor cells. In conclusion, our findings provide a novel insight into ovarian cancer cells influence the immune system in the tumor microenvironment and highlight the potential clinical implication of combination of immune checkpoints with GLS inhibitor 968 in treating ovarian cancer. Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of tumors, including ovarian cancer. Kidney-type glutaminase (GLS), as one of the isotypes of glutaminase, is found to promote tumorigenesis. Here, we have demonstrated that the combined treatment with GLS inhibitor 968 and PD-L1 blockade enhances the immune response against ovarian cancer. Survival analysis using the Kaplan–Meier plotter dataset from ovarian cancer patients revealed that the expression level of GLS predicts poor survival and correlates with the immunosuppressive microenvironment of ovarian cancer. 968 inhibits the proliferation of ovarian cancer cells and enhances granzyme B secretion by CD8 + T cells as detected by XTT assay and flow cytometry, respectively. Furthermore, 968 enhances the apoptosis-inducing ability of CD8 + T cells toward cancer cells and improves the treatment effect of anti-PD-L1 in treating ovarian cancer as assessed by Annexin V apoptosis assay. In vivo studies demonstrated the prolonged overall survival upon combined treatment of 968 with anti-PD-L1 accompanied by increased granzyme B secretion by CD4 + and CD8 + T cells isolated from ovarian tumor xenografts. Additionally, 968 increases the infiltration of CD3 + T cells into tumors, possibly through enhancing the secretion of CXCL10 and CXCL11 by tumor cells. In conclusion, our findings provide a novel insight into ovarian cancer cells influence the immune system in the tumor microenvironment and highlight the potential clinical implication of combination of immune checkpoints with GLS inhibitor 968 in treating ovarian cancer. Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of tumors, including ovarian cancer. Kidney-type glutaminase (GLS), as one of the isotypes of glutaminase, is found to promote tumorigenesis. Here, we have demonstrated that the combined treatment with GLS inhibitor 968 and PD-L1 blockade enhances the immune response against ovarian cancer. Survival analysis using the Kaplan–Meier plotter dataset from ovarian cancer patients revealed that the expression level of GLS predicts poor survival and correlates with the immunosuppressive microenvironment of ovarian cancer. 968 inhibits the proliferation of ovarian cancer cells and enhances granzyme B secretion by CD8+ T cells as detected by XTT assay and flow cytometry, respectively. Furthermore, 968 enhances the apoptosis-inducing ability of CD8+ T cells toward cancer cells and improves the treatment effect of anti-PD-L1 in treating ovarian cancer as assessed by Annexin V apoptosis assay. In vivo studies demonstrated the prolonged overall survival upon combined treatment of 968 with anti-PD-L1 accompanied by increased granzyme B secretion by CD4+ and CD8+ T cells isolated from ovarian tumor xenografts. Additionally, 968 increases the infiltration of CD3+ T cells into tumors, possibly through enhancing the secretion of CXCL10 and CXCL11 by tumor cells. In conclusion, our findings provide a novel insight into ovarian cancer cells influence the immune system in the tumor microenvironment and highlight the potential clinical implication of combination of immune checkpoints with GLS inhibitor 968 in treating ovarian cancer. Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of tumors, including ovarian cancer. Kidney-type glutaminase (GLS), as one of the isotypes of glutaminase, is found to promote tumorigenesis. Here, we have demonstrated that the combined treatment with GLS inhibitor 968 and PD-L1 blockade enhances the immune response against ovarian cancer. Survival analysis using the Kaplan-Meier plotter dataset from ovarian cancer patients revealed that the expression level of GLS predicts poor survival and correlates with the immunosuppressive microenvironment of ovarian cancer. 968 inhibits the proliferation of ovarian cancer cells and enhances granzyme B secretion by CD8 T cells as detected by XTT assay and flow cytometry, respectively. Furthermore, 968 enhances the apoptosis-inducing ability of CD8 T cells toward cancer cells and improves the treatment effect of anti-PD-L1 in treating ovarian cancer as assessed by Annexin V apoptosis assay. In vivo studies demonstrated the prolonged overall survival upon combined treatment of 968 with anti-PD-L1 accompanied by increased granzyme B secretion by CD4 and CD8 T cells isolated from ovarian tumor xenografts. Additionally, 968 increases the infiltration of CD3 T cells into tumors, possibly through enhancing the secretion of CXCL10 and CXCL11 by tumor cells. In conclusion, our findings provide a novel insight into ovarian cancer cells influence the immune system in the tumor microenvironment and highlight the potential clinical implication of combination of immune checkpoints with GLS inhibitor 968 in treating ovarian cancer. |
| Author | Siu, Michelle Kwan-Yee Jiang, Yu-Xin Chan, David Wai Wang, Jing-Jing Leung, Thomas Ho-Yin Wang, Huo-Gang Ngan, Hextan Yuen-Sheung Chan, Karen Kar-Loen |
| AuthorAffiliation | Departments of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong, China; wjj01947@163.com (J.-J.W.); mkysiu@gmail.com (M.K.-Y.S.); yuxin_jiang2012@126.com (Y.-X.J.); thomashyleung@gmail.com (T.H.-Y.L.); dwchan@hku.hk (D.W.C.); wanghuog@connect.hku.hk (H.-G.W.); hysngan@hku.hk (H.Y.-S.N.) |
| AuthorAffiliation_xml | – name: Departments of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong, China; wjj01947@163.com (J.-J.W.); mkysiu@gmail.com (M.K.-Y.S.); yuxin_jiang2012@126.com (Y.-X.J.); thomashyleung@gmail.com (T.H.-Y.L.); dwchan@hku.hk (D.W.C.); wanghuog@connect.hku.hk (H.-G.W.); hysngan@hku.hk (H.Y.-S.N.) |
| Author_xml | – sequence: 1 givenname: Jing-Jing surname: Wang fullname: Wang, Jing-Jing – sequence: 2 givenname: Michelle Kwan-Yee surname: Siu fullname: Siu, Michelle Kwan-Yee – sequence: 3 givenname: Yu-Xin surname: Jiang fullname: Jiang, Yu-Xin – sequence: 4 givenname: Thomas Ho-Yin surname: Leung fullname: Leung, Thomas Ho-Yin – sequence: 5 givenname: David Wai orcidid: 0000-0002-6951-3467 surname: Chan fullname: Chan, David Wai – sequence: 6 givenname: Huo-Gang orcidid: 0000-0001-8127-7842 surname: Wang fullname: Wang, Huo-Gang – sequence: 7 givenname: Hextan Yuen-Sheung surname: Ngan fullname: Ngan, Hextan Yuen-Sheung – sequence: 8 givenname: Karen Kar-Loen surname: Chan fullname: Chan, Karen Kar-Loen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34944392$$D View this record in MEDLINE/PubMed |
| BookMark | eNptks1rFDEUwAep2Fp78ywBLx4cnXzMJLkI7ap1YaEiCt7Cm0yym3UmWZNMwf_etFvLthgCCS-_98vXe14d-eBNVb3EzTtKZfO-d2HCGBPMmXxSnRCCRU04_Xl0MD-uzlLaNqWJ0gl9Vh1TJhmjkpxU4RwtwtQ7D9kFj4JFl-OcYSqBZNDSb1zvcohIdgKBH9DXj_UKo4sx6F8wGHQRQsoJ5U1hp2n2Bn0zaRd8yYU1OJ8yurqG6MCjBXht4ovqqYUxmbO78bT68fnT98WXenV1uVycr2rNuMg1MyClsAQzjAfOKAbLGeGWtw02UrNG95SStrMWho5rYBZ412I7NIQz0Qt6Wi333iHAVu2imyD-UQGcug2EuFYQs9OjUUUzENMzMfQtA2b6zjLSYN30DJNWkuL6sHft5n4ygzY-RxgfSB-ueLdR63CtRCdFK9oieHMniOH3bFJWk0vajCN4E-akSIcZoWUrXNDXj9BtmKMvT3VDEd4SxmShXh2e6P4o__61AG_3gI4hpWjsPYIbdVM56rByCk4e4drl24oo93Hj_5P-Au5lxPA |
| CitedBy_id | crossref_primary_10_1016_j_tibs_2023_03_004 crossref_primary_10_1002_jcp_31495 crossref_primary_10_3390_metabo13050618 crossref_primary_10_1111_jcmm_18198 crossref_primary_10_1002_ctm2_70012 crossref_primary_10_3389_fphar_2024_1345522 crossref_primary_10_3389_fimmu_2022_1030831 crossref_primary_10_3390_ijms232315296 crossref_primary_10_3390_metabo14030170 crossref_primary_10_1136_ijgc_2024_005920 crossref_primary_10_1016_j_bbcan_2024_189107 crossref_primary_10_1186_s13046_024_02994_0 crossref_primary_10_1016_j_pharmthera_2023_108413 crossref_primary_10_1016_j_ejmech_2022_114337 crossref_primary_10_1007_s00432_022_04501_4 crossref_primary_10_3389_fonc_2022_1018642 crossref_primary_10_3390_cimb47030172 crossref_primary_10_1016_j_bioactmat_2024_08_028 crossref_primary_10_1038_s41598_024_84916_w crossref_primary_10_1007_s11684_023_1025_7 crossref_primary_10_3389_fonc_2023_1143798 crossref_primary_10_3390_ijms23126857 crossref_primary_10_1002_INMD_20240069 crossref_primary_10_1016_j_bcp_2023_115724 crossref_primary_10_32604_biocell_2023_028968 crossref_primary_10_59717_j_xinn_life_2024_100128 |
| Cites_doi | 10.1111/jog.13521 10.1093/nar/gkx247 10.1158/0008-5472.CAN-18-3208 10.1016/j.jim.2020.112899 10.1158/0008-5472.CAN-15-1142 10.1136/jclinpath-2017-204853 10.1007/s00262-017-2005-z 10.1016/j.ctrv.2017.11.007 10.1158/0008-5472.CAN-14-3098 10.1056/NEJMoa1507643 10.3389/fimmu.2018.01739 10.1002/path.3029 10.18632/oncotarget.14188 10.1016/S0171-2985(87)80019-0 10.1056/NEJMoa1200694 10.2217/imt-2018-0111 10.1111/jdv.13567 10.18632/oncotarget.21286 10.1200/JCO.2015.62.3397 10.3233/KCA-180043 10.1158/0008-5472.CAN-13-1550 10.1038/icb.2010.158 10.1158/1055-9965.EPI-16-0641 10.1016/j.critrevonc.2018.12.003 10.1038/bjc.2016.172 10.1126/scitranslmed.3003689 10.1111/cas.13827 10.1172/JCI87324 10.1016/j.ccr.2010.08.009 10.4049/jimmunol.1502376 10.1002/pros.21486 10.1136/ijgc-2018-000011 10.1016/j.ygyno.2018.07.025 10.1074/jbc.M117.810101 10.1038/ncomms11406 10.18632/oncotarget.9317 10.1038/ni.3201 10.1186/s40425-018-0349-3 10.1002/msb.20134892 10.1016/j.cell.2018.10.001 10.1200/jco.2015.33.15_suppl.5510 10.3390/ijms20020252 10.18632/oncotarget.3196 10.1016/j.intimp.2017.08.017 10.1038/nm730 10.1016/0014-5793(94)80236-X 10.1073/pnas.0611533104 10.1038/onc.2009.358 10.1038/s41598-019-39345-5 10.3390/antib2010019 10.1172/JCI140100 10.1084/jem.192.7.1027 10.1016/S1074-7613(03)00032-3 10.1126/science.aav2588 10.1158/1078-0432.CCR-16-0387 |
| ContentType | Journal Article |
| Copyright | 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2021 by the authors. 2021 |
| Copyright_xml | – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2021 by the authors. 2021 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7TM 7TO 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.3390/biom11121749 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 2218-273X |
| ExternalDocumentID | oai_doaj_org_article_256d2eb48db54a4eb6f4201c0b412592 PMC8698585 34944392 10_3390_biom11121749 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Hong Kong China Canada United States--US |
| GeographicLocations_xml | – name: Hong Kong China – name: Canada – name: United States--US |
| GroupedDBID | 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFKRA AFPKN AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CITATION EBD ESX FYUFA GROUPED_DOAJ HCIFZ HMCUK HYE IAO IHR ITC KQ8 LK8 M1P M48 M7P MODMG M~E OK1 PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RPM UKHRP 3V. CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7XB 8FK AZQEC DWQXO GNUQQ H94 K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c478t-4ea998f21411d7431af7427f7501e9c40cb33256ffad67ca4fa7651fd02748b83 |
| IEDL.DBID | M48 |
| ISSN | 2218-273X |
| IngestDate | Wed Aug 27 01:21:05 EDT 2025 Thu Aug 21 14:20:46 EDT 2025 Thu Jul 10 22:03:38 EDT 2025 Fri Jul 25 12:08:04 EDT 2025 Thu Jan 02 22:56:25 EST 2025 Tue Jul 01 02:05:32 EDT 2025 Thu Apr 24 23:02:32 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | glutamine metabolism T cells ovarian cancer immunotherapy |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c478t-4ea998f21411d7431af7427f7501e9c40cb33256ffad67ca4fa7651fd02748b83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 J.-J.W. and M.K.-Y.S. contributed equally to this work. |
| ORCID | 0000-0002-6951-3467 0000-0001-8127-7842 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/biom11121749 |
| PMID | 34944392 |
| PQID | 2612752449 |
| PQPubID | 2032425 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_256d2eb48db54a4eb6f4201c0b412592 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8698585 proquest_miscellaneous_2614235921 proquest_journals_2612752449 pubmed_primary_34944392 crossref_primary_10_3390_biom11121749 crossref_citationtrail_10_3390_biom11121749 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20211123 |
| PublicationDateYYYYMMDD | 2021-11-23 |
| PublicationDate_xml | – month: 11 year: 2021 text: 20211123 day: 23 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Biomolecules (Basel, Switzerland) |
| PublicationTitleAlternate | Biomolecules |
| PublicationYear | 2021 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Yang (ref_14) 2014; 10 Fucikova (ref_51) 2016; 76 Yan (ref_37) 2018; 9 Bronger (ref_36) 2016; 115 Prizment (ref_26) 2017; 26 Zhang (ref_34) 2019; 11 Varga (ref_9) 2015; 33 ref_11 Aloyz (ref_13) 2019; 134 ref_54 Yuan (ref_19) 2016; 8 Goping (ref_46) 2003; 18 Ray (ref_47) 2012; 72 Wang (ref_17) 2010; 18 Groom (ref_57) 2011; 89 DeBerardinis (ref_10) 2010; 29 Horikawa (ref_52) 2017; 23 Iwahori (ref_21) 2019; 9 Yu (ref_41) 2015; 6 Gavalas (ref_32) 2010; 2010 Borghaei (ref_39) 2015; 373 Droge (ref_43) 1987; 174 Chheda (ref_58) 2016; 197 Leone (ref_15) 2019; 366 Duraiswamy (ref_50) 2013; 73 Pinto (ref_3) 2018; 151 Marth (ref_1) 2019; 29 Xiong (ref_49) 2019; 79 Ventola (ref_2) 2017; 42 Hamanishi (ref_8) 2015; 33 Chen (ref_28) 2017; 66 Huang (ref_16) 2018; 293 Schiffer (ref_27) 2013; 2 Johnson (ref_45) 2018; 175 Brahmer (ref_31) 2012; 366 Zhu (ref_6) 2018; 44 Han (ref_18) 2017; 8 Kistner (ref_35) 2017; 8 Kythreotou (ref_5) 2018; 71 Hoerner (ref_12) 2019; 3 Rousalova (ref_25) 2010; 37 Tokunaga (ref_56) 2018; 63 Hudson (ref_40) 2016; 7 Hamanishi (ref_4) 2007; 104 Wang (ref_33) 2017; 52 Tang (ref_24) 2017; 45 Yaromina (ref_22) 2020; 487 Balkwill (ref_55) 2012; 226 Anegawa (ref_48) 2016; 30 Taube (ref_29) 2012; 4 Freeman (ref_30) 2000; 192 Daud (ref_53) 2016; 126 Dong (ref_23) 2002; 8 Nabe (ref_44) 2018; 109 Aledo (ref_42) 1994; 341 Laird (ref_59) 2015; 16 Peng (ref_7) 2015; 75 Chae (ref_38) 2018; 6 Xu (ref_20) 2016; 7 |
| References_xml | – volume: 44 start-page: 303 year: 2018 ident: ref_6 article-title: Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model publication-title: J. Obstet. Gynaecol. Res. doi: 10.1111/jog.13521 – volume: 42 start-page: 375 year: 2017 ident: ref_2 article-title: Cancer immunotherapy, part 1: Current strategies and agents publication-title: Pharm. Ther. – volume: 45 start-page: W98 year: 2017 ident: ref_24 article-title: Gepia: A web server for cancer and normal gene expression profiling and interactive analyses publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkx247 – volume: 2010 start-page: 791603 year: 2010 ident: ref_32 article-title: Immune response in ovarian cancer: How is the immune system involved in prognosis and therapy: Potential for treatment utilization publication-title: Clin. Dev. Immunol. – volume: 79 start-page: 1493 year: 2019 ident: ref_49 article-title: Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-3208 – volume: 487 start-page: 112899 year: 2020 ident: ref_22 article-title: A novel co-culture assay to assess anti-tumor CD8(+) T cell cytotoxicity via luminescence and multicolor flow cytometry publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2020.112899 – volume: 76 start-page: 1746 year: 2016 ident: ref_51 article-title: Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-15-1142 – volume: 71 start-page: 189 year: 2018 ident: ref_5 article-title: Pd-l1 publication-title: J. Clin. Pathol. doi: 10.1136/jclinpath-2017-204853 – volume: 66 start-page: 1175 year: 2017 ident: ref_28 article-title: Kras mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-017-2005-z – volume: 63 start-page: 40 year: 2018 ident: ref_56 article-title: CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation—A target for novel cancer therapy publication-title: Cancer Treat. Rev. doi: 10.1016/j.ctrv.2017.11.007 – volume: 75 start-page: 5034 year: 2015 ident: ref_7 article-title: Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-3098 – volume: 373 start-page: 1627 year: 2015 ident: ref_39 article-title: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1507643 – volume: 9 start-page: 1739 year: 2018 ident: ref_37 article-title: Combining immune checkpoint inhibitors with conventional cancer therapy publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.01739 – volume: 226 start-page: 148 year: 2012 ident: ref_55 article-title: The chemokine system and cancer publication-title: J. Pathol. doi: 10.1002/path.3029 – volume: 8 start-page: 28063 year: 2017 ident: ref_18 article-title: A novel glutaminase inhibitor-968 inhibits the migration and proliferation of non-small cell lung cancer cells by targeting EGFR/ERK signaling pathway publication-title: Oncotarget doi: 10.18632/oncotarget.14188 – volume: 174 start-page: 473 year: 1987 ident: ref_43 article-title: Elevated plasma glutamate levels in colorectal carcinoma patients and in patients with acquired immunodeficiency syndrome (aids) publication-title: Immunobiology doi: 10.1016/S0171-2985(87)80019-0 – volume: 366 start-page: 2455 year: 2012 ident: ref_31 article-title: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1200694 – volume: 11 start-page: 201 year: 2019 ident: ref_34 article-title: Enhancing tumor t cell infiltration to enable cancer immunotherapy publication-title: Immunotherapy doi: 10.2217/imt-2018-0111 – volume: 8 start-page: 4265 year: 2016 ident: ref_19 article-title: Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer publication-title: Am. J. Transl. Res. – volume: 30 start-page: e231 year: 2016 ident: ref_48 article-title: Upregulation of granzyme B and interferon-gamma mRNA in responding lesions by treatment with nivolumab for metastatic melanoma: A case report publication-title: J. Eur. Acad. Dermatol. Venereol. doi: 10.1111/jdv.13567 – volume: 8 start-page: 89998 year: 2017 ident: ref_35 article-title: Interferon-inducible cxc-chemokines are crucial immune modulators and survival predictors in colorectal cancer publication-title: Oncotarget doi: 10.18632/oncotarget.21286 – volume: 33 start-page: 4015 year: 2015 ident: ref_8 article-title: Safety and antitumor activity of anti-pd-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.62.3397 – volume: 3 start-page: 15 year: 2019 ident: ref_12 article-title: The ‘Achilles heel’ of metabolism in renal cell carcinoma: Glutaminase inhibition as a rational treatment strategy publication-title: Kidney Cancer doi: 10.3233/KCA-180043 – volume: 73 start-page: 6900 year: 2013 ident: ref_50 article-title: Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-1550 – volume: 89 start-page: 207 year: 2011 ident: ref_57 article-title: CXCR3 ligands: Redundant, collaborative and antagonistic functions publication-title: Immunol. Cell Biol. doi: 10.1038/icb.2010.158 – volume: 26 start-page: 622 year: 2017 ident: ref_26 article-title: Cytotoxic t cells and granzyme b associated with improved colorectal cancer survival in a prospective cohort of older women publication-title: Cancer Epidemiol. Biomark. Prev. doi: 10.1158/1055-9965.EPI-16-0641 – volume: 134 start-page: 65 year: 2019 ident: ref_13 article-title: Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know? publication-title: Crit. Rev. Oncol. Hematol. doi: 10.1016/j.critrevonc.2018.12.003 – volume: 115 start-page: 553 year: 2016 ident: ref_36 article-title: CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer publication-title: Br. J. Cancer doi: 10.1038/bjc.2016.172 – volume: 4 start-page: 127ra137 year: 2012 ident: ref_29 article-title: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.3003689 – volume: 109 start-page: 3737 year: 2018 ident: ref_44 article-title: Reinforce the antitumor activity of CD8(+) T cells via glutamine restriction publication-title: Cancer Sci. doi: 10.1111/cas.13827 – volume: 126 start-page: 3447 year: 2016 ident: ref_53 article-title: Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma publication-title: J. Clin. Investig. doi: 10.1172/JCI87324 – volume: 18 start-page: 207 year: 2010 ident: ref_17 article-title: Targeting mitochondrial glutaminase activity inhibits oncogenic transformation publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.08.009 – volume: 197 start-page: 2016 year: 2016 ident: ref_58 article-title: Chemoattractant receptors BLT1 and CXCR3 regulate antitumor immunity by facilitating CD8+ T cell migration into tumors publication-title: J. Immunol. doi: 10.4049/jimmunol.1502376 – volume: 72 start-page: 846 year: 2012 ident: ref_47 article-title: Inhibition of granzyme B by PI-9 protects prostate cancer cells from apoptosis publication-title: Prostate doi: 10.1002/pros.21486 – volume: 29 start-page: 201 year: 2019 ident: ref_1 article-title: Immunotherapy in ovarian cancer: Fake news or the real deal? publication-title: Int. J. Gynecol. Cancer doi: 10.1136/ijgc-2018-000011 – volume: 151 start-page: 10 year: 2018 ident: ref_3 article-title: Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2018.07.025 – volume: 293 start-page: 3535 year: 2018 ident: ref_16 article-title: Characterization of the interactions of potent allosteric inhibitors with glutaminase c, a key enzyme in cancer cell glutamine metabolism publication-title: J. Biol. Chem. doi: 10.1074/jbc.M117.810101 – volume: 7 start-page: 11406 year: 2016 ident: ref_20 article-title: miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint publication-title: Nat. Commun. doi: 10.1038/ncomms11406 – volume: 7 start-page: 41637 year: 2016 ident: ref_40 article-title: Altered glutamine metabolism in platinum resistant ovarian cancer publication-title: Oncotarget doi: 10.18632/oncotarget.9317 – volume: 16 start-page: 850 year: 2015 ident: ref_59 article-title: Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy publication-title: Nat. Immunol. doi: 10.1038/ni.3201 – volume: 6 start-page: 39 year: 2018 ident: ref_38 article-title: Current landscape and future of dual anti-CTLA4 and PD-1/PD-l1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) publication-title: J. Immunother. Cancer doi: 10.1186/s40425-018-0349-3 – volume: 10 start-page: 728 year: 2014 ident: ref_14 article-title: Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer publication-title: Mol. Syst. Biol. doi: 10.1002/msb.20134892 – volume: 175 start-page: 1780 year: 2018 ident: ref_45 article-title: Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism publication-title: Cell doi: 10.1016/j.cell.2018.10.001 – volume: 33 start-page: 5510 year: 2015 ident: ref_9 article-title: Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study publication-title: J. Clin. Oncol. doi: 10.1200/jco.2015.33.15_suppl.5510 – volume: 37 start-page: 1361 year: 2010 ident: ref_25 article-title: Granzyme b-induced apoptosis in cancer cells and its regulation (review) publication-title: Int. J. Oncol. – ident: ref_11 doi: 10.3390/ijms20020252 – volume: 6 start-page: 7619 year: 2015 ident: ref_41 article-title: Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma publication-title: Oncotarget doi: 10.18632/oncotarget.3196 – volume: 52 start-page: 7 year: 2017 ident: ref_33 article-title: Prognostic value of tumor PD-L1 expression combined with CD8(+) tumor infiltrating lymphocytes in high grade serous ovarian cancer publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2017.08.017 – volume: 8 start-page: 793 year: 2002 ident: ref_23 article-title: Tumor-associated B7-h1 promotes T-cell apoptosis: A potential mechanism of immune evasion publication-title: Nat. Med. doi: 10.1038/nm730 – volume: 341 start-page: 39 year: 1994 ident: ref_42 article-title: Phosphate-activated glutaminase expression during tumor development publication-title: FEBS Lett. doi: 10.1016/0014-5793(94)80236-X – volume: 104 start-page: 3360 year: 2007 ident: ref_4 article-title: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0611533104 – volume: 29 start-page: 313 year: 2010 ident: ref_10 article-title: Q’s next: The diverse functions of glutamine in metabolism, cell biology and cancer publication-title: Oncogene doi: 10.1038/onc.2009.358 – volume: 9 start-page: 2636 year: 2019 ident: ref_21 article-title: Peripheral t cell cytotoxicity predicts t cell function in the tumor microenvironment publication-title: Sci. Rep. doi: 10.1038/s41598-019-39345-5 – volume: 2 start-page: 19 year: 2013 ident: ref_27 article-title: Improving the therapeutic potential of human granzyme B for targeted cancer therapy publication-title: Antibodies doi: 10.3390/antib2010019 – ident: ref_54 doi: 10.1172/JCI140100 – volume: 192 start-page: 1027 year: 2000 ident: ref_30 article-title: Engagement of the pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation publication-title: J. Exp. Med. doi: 10.1084/jem.192.7.1027 – volume: 18 start-page: 355 year: 2003 ident: ref_46 article-title: Granzyme b-induced apoptosis requires both direct caspase activation and relief of caspase inhibition publication-title: Immunity doi: 10.1016/S1074-7613(03)00032-3 – volume: 366 start-page: 1013 year: 2019 ident: ref_15 article-title: Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion publication-title: Science doi: 10.1126/science.aav2588 – volume: 23 start-page: 587 year: 2017 ident: ref_52 article-title: Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-0387 |
| SSID | ssj0000800823 |
| Score | 2.381033 |
| Snippet | Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1749 |
| SubjectTerms | Animals Annexin V Antibodies Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - pharmacology Apoptosis Benzophenanthridines - administration & dosage Benzophenanthridines - pharmacology Cancer therapies CD3 antigen CD4 antigen CD8 antigen Cell culture Cell death Cell Line, Tumor Cell proliferation Cell Proliferation - drug effects Cell Survival - drug effects Chemokines Clinical outcomes CXCL10 protein CXCL11 protein Drug Synergism Female Flow cytometry Gene expression Gene Expression Regulation, Neoplastic - drug effects Glutaminase Glutaminase - genetics Glutamine glutamine metabolism Granzyme B Humans Immune checkpoint Immune Checkpoint Inhibitors - administration & dosage Immune Checkpoint Inhibitors - pharmacology Immune response Immune system Immunotherapy Isotypes Kidneys Lung cancer Lymphocytes Lymphocytes T Medical prognosis Metabolism Metastases Mice Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism PD-L1 protein T cells Treatment Outcome Tumor cells Tumor microenvironment Tumor Microenvironment - drug effects Tumorigenesis Tumors Xenograft Model Antitumor Assays Xenografts |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQUB4LBQ0ScEFR43iSOMfdQmkRLyEq9RbZsU0XWgftbpH498w46WoXgbhwjS3Hnkfm--LxWIinEsugytxljS0wQ495pmUdsk51dRU657Ti08jv3ldHJ_jmtDzduOqLc8KG8sCD4PYpJLvCW9TOlmjQ2yogBa0ut0ixuUlfX4p5G2Tq64iDdKGGTHdFvH6fT7OTXzMCb7ZiUCrV_yd8-Xua5EbcObwpboyAEabDRG-Jaz7eFrvTSGT54ic8h5TCmf6N74p-CuTfxHWTuKEP8JoMy3C2y9LDcTybW3LgBTSVBhMdfHyZvZUwo3j2zTgPs75frpZAkBCO-diIh09DBq0H88XMCUjChx_ErU2EAzaWxR1xcvjq88FRNt6okHVY6xXpwhC9CoVEKR1jBxOIGteBYIP0TYd5Z5UiiYdgXFV3BoOpq1IGx-RVW63uip3YR39fQFWqgKQZnXtCCNhYR6P5oNBZgwRrJuLFlYzbbiw3zrdenLdEO1gj7aZGJuLZuvf3oczGX_rNWF3rPlwcOz0gk2lHk2n_ZTITsXel7Hb02GXLpdTqkpZC73iybiZf4w0UE31_mfoQ-qQR5ETcG2xjPRMu80Pgjgavt6xma6rbLXF-lup566rh3dkH_2NtD8X1grNupMwKtSd2VotL_4hg08o-Th7yC2wPFO8 priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagXLggoDxCCxok4IKirmMndk5ot1BaxEuISnuL_GxXhaTdbJH498wk2dBFwDW2rIlnxv4-ezzD2DMu8yjyiU9Lm8lUBjlJNVcxdcKpIjrvtaDXyB8-FofH8t08nw8Hbu0QVrleE7uF2jeOzsj3KNWVynEzKl-dX6RUNYpuV4cSGtfZDUpdRuRLzdV4xkJoSGeij3cXyO736E07ejfh8HJjJ-oS9v8NZf4ZLHll9zm4zW4NsBGmvZ7vsGuhvsu2pzVS5u8_4QV0gZzdCfk2a6aAXo6Mt5t0aCK8RfMyFPPSBjiqTxcW3XgJZaHB1B4-v07fc5jhrnZmfIBZ07SrFhAYwhE9HgnwpY-jDWBOzALhJHz6gQzb1LBPJrO8x44P3nzdP0yHugqpk0qvUCMGSVbMuOTcE4IwEQmyiggeeCidnDgrBEKhGI0vlDMyGlXkPHqisNpqcZ9t1U0dHjIochGlz4KeBFSNLK3H0UIU0lsjEdwk7OV6jis3JB2n2hffKiQfpJHqqkYS9nzsfd4n2_hHvxmpa-xDKbK7D83ypBo8rsIfQMGs1N7m0shgiygR7biJlQjqyixhu2tlV4PfttVvK0vY07EZPY6uUUwdmsuuD2JQHIEn7EFvG6MklOwHIR4OrjasZkPUzZZ6cdpl9dZFSXe0j_4v1g67mVFUDedpJnbZ1mp5GR4jLFrZJ53t_wLOQgzd priority: 102 providerName: ProQuest |
| Title | A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34944392 https://www.proquest.com/docview/2612752449 https://www.proquest.com/docview/2614235921 https://pubmed.ncbi.nlm.nih.gov/PMC8698585 https://doaj.org/article/256d2eb48db54a4eb6f4201c0b412592 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB71IaFeEFCgKWVlJOCCAnHsxM4Bod3S0iJaqoqV9hbZsd0uLQlkt4j-e8Z5rLpQLlyTSWJnZjTfZ49nAJ5TnjiWRCbMdMxDbnkUSipcWLBCpK4wRjJ_GvnoOD0Y84-TZLICfbfR7gfObqV2vp_UuL58_evH9Tt0-LeecSJlf-MPqqPLenCdrcI6xiThmzgcdUD_a4eLZMzazPe_HtqAO75KC8bmeCk8NVX8b4Oef2ZQ3ghJ-_fgboclybBV_n1YseUD2ByWyKO_XZOXpMnubJbNN6EaEnR9pMGNJkjlyAe0OeUTYWaWHJbnU42-XZMslUSVhpy8Dz9RMsJQd6GMJaOqms1nBNEiOfQnSiw5bZNrLVFnaooYk3z-ibRblWTX21H9EMb7e192D8Ku2UJYcCHnqCaFzMvFlFNqPKxQDlmzcIgoqM0KHhWaMcRHzimTikJxp0SaUGc8r5VaskewVlal3QKSJsxxE1sZWQQPPNMG32Yd40YrjogngFf9P86LrhK5b4hxmSMj8crJbyongBcL6e9tBY5_yI28uhYyvm52c6Gqz_LODXOcAA5Mc2l0whW3OnUcIVARaY5IL4sD2OmVnfe2mPsqayLBqeA3ni1uoxv6vRVV2uqqkUFgim-gATxubWMxkt62AhBLVrM01OU75fS8KfUt08xv3G7_95NPYCP2WTiUhjHbgbV5fWWfIoya6wGsiokYwPpo7_jkdNAsRgwar_kNSO0gVg |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOcAFAeURKGAkygVFjWMnTg4I7baUXbotCLXS3lI7ttsVbVI2W1D_FL-RmbzoIuDWa-JYE8945ht7HoS8YiJyPAqMn-pQ-MKKwE-YdH7Ocxm73JiEYzby3n48OhQfp9F0hfzscmEwrLLTibWiNmWOZ-SbWOpKRmCM0nfn33zsGoW3q10LjUYsdu3lD3DZqrfjbeDvRhjuvD_YGvltVwE_FzJZAD0KXAwXMsGYQfupHLiH0oHpZDbNRZBrzgEIOKdMLHMlnJJxxJxBBy7RCYd5b5Cb8GGAIYRyKvszHURfScib-HrO02ATc-hBmyDuT5csX90g4G-o9s_gzCvWbucuudPCVDpo5OoeWbHFfbI2KMBFP7ukr2kdOFqfyK-RckBBq4CHXTOZlo5-AHFWGGNTWTouTmYa1MacpnFCVWHo521_wugQrOhXZSwdlmW1qCgAUTrGZBVLvzRxu5aqYzUD-Eo_fQePXhV0C0V0_oAcXsuKPySrRVnYx4TGEXfChDYJLIiCSLWB2azjwmglAEx55E23xlneFjnHXhunGTg7yJHsKkc8stGPPm-Ke_xj3BDZ1Y_Bktz1g3J-nLU7PIMfAMK0SIyOhBJWx04AusoDLQBEpqFH1jtmZ62eqLLfUu2Rl_1r2OF4baMKW17UYwDzwgzMI48a2egpweJCAClhcrkkNUukLr8pZid1FfEkTvFO-Mn_yXpBbo0O9ibZZLy_-5TcDjGihzE_5OtkdTG_sM8Aki3083ofUHJ03RvvF_yVSNQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkRAXBJRHSgEjUS4o2jh24uSA0G6XpUtLqRCV9hbs2G5XlKRstqD-NX4dM3nRRcCt19iyJp7XN_Z4hpDnTESOR4HxUx0KX1gR-AmTzs95LmOXG5NwfI38_iDePRLvZtFsjfzs3sJgWmVnE2tDbcocz8gHWOpKRuCM0oFr0yIOx5PXZ9987CCFN61dO41GRPbsxQ8I36pX0zHwejsMJ28-7ez6bYcBPxcyWQJtCsINFzLBmEFfqhyEitKBG2U2zUWQa84BFDinTCxzJZySccScwWAu0QmHda-R65KD2wRdkjPZn-8gEktC3uTac54GA3xPD5YFY4B0xQvWzQL-hnD_TNS85Pkmt8mtFrLSYSNjd8iaLe6SjWEB4frXC_qC1kmk9en8BimHFCwMRNs1w2np6FsQbYX5NpWl0-JkrsGELGgaJ1QVhh6O_X1GR-BRvyhj6agsq2VFAZTSKT5csfRjk8NrqTpWc4Cy9MN3iO5VQXdQXBf3yNGV7Ph9sl6UhX1IaBxxJ0xok8CCWIhUG1jNOi6MVgKAlUdednuc5W3Bc-y7cZpB4IMcyS5zxCPb_eyzptDHP-aNkF39HCzPXX8oF8dZq-0Z_AAQpkVidCSUsDp2ApBWHmgBgDINPbLVMTtrbUaV_ZZwjzzrh0Hb8QpHFbY8r-cA_oUVmEceNLLRU4KFhgBewuJyRWpWSF0dKeYndUXxJE7xfnjz_2Q9JTdA5bL96cHeI3IzxOQexvyQb5H15eLcPgZ0ttRPajWg5PNV690vQexNCg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Combination+of+Glutaminase+Inhibitor+968+and+PD-L1+Blockade+Boosts+the+Immune+Response+against+Ovarian+Cancer&rft.jtitle=Biomolecules+%28Basel%2C+Switzerland%29&rft.au=Wang%2C+Jing-Jing&rft.au=Siu%2C+Michelle+Kwan-Yee&rft.au=Jiang%2C+Yu-Xin&rft.au=Leung%2C+Thomas+Ho-Yin&rft.date=2021-11-23&rft.pub=MDPI&rft.eissn=2218-273X&rft.volume=11&rft.issue=12&rft_id=info:doi/10.3390%2Fbiom11121749&rft_id=info%3Apmid%2F34944392&rft.externalDocID=PMC8698585 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2218-273X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2218-273X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2218-273X&client=summon |